Federal
Register Notices > Importers
>
Lipomed, Inc
FR Doc E7-12954 [Federal Register: July 3, 2007 (Volume 72, Number 127)]
[Notices] [Page 36482-36483] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr03jy07-88]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this is
notice that on February 2, 2007, Lipomed, Inc., One Broadway, Cambridge,
Massachusetts 02142, made application by renewal to the Drug Enforcement
Administration (DEA) for registration as an importer of the basic classes of
controlled substances listed in schedules II:
Drug
|
Schedule
|
Cathinone (1235)
|
I
|
Methcathinone (1237)
|
I
|
N-Ethylamphetamine (1475)
|
I
|
Methaqualone (2565)
|
I
|
Gamma Hydroxybutyric Acid (2010)
|
I
|
Lysergic acid diethylamide (7315)
|
I
|
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348)
|
I
|
Marihuana (7360)
|
I
|
Tetrahydrocannabinols (7370)
|
I
|
Mescaline (7381)
|
I
|
3,4,5-Trimethoxyamphetamine (7390)
|
I
|
4-Bromo-2,5-dimethoxyamphetamine (7391)
|
I
|
4-Bromo-2,5-dimethoxyphenethylamine (7392)
|
I
|
4-Methyl-2,5-dimethoxyamphetamine (7395)
|
I
|
2,5-Dimethoxyamphetamine (7396)
|
I
|
2,5-Dimethoxy-4-ethylamphetamine (7399)
|
I
|
3,4-Methylenedioxyamphetamine (7400)
|
I
|
3,4-Methylenedioxy-N-ethylamphetamine (7404)
|
I
|
3,4-Methylenedioxymethamphetamine (7405)
|
I
|
4-Methoxyamphetamine (7411)
|
I
|
Dimethyltryptamine (7435)
|
I
|
Psilocybin (7437)
|
I
|
Psilocyn (7438)
|
I
|
Acetyldihydrocodeine (9051)
|
I
|
Dihydromorphine (9145)
|
I
|
Heroin (9200)
|
I
|
Normorphine (9313)
|
I
|
Pholcodine (9314)
|
I
|
Tilidine (9750)
|
I
|
Amphetamine (1100)
|
II
|
Methamphetamine (1105)
|
II
|
Amobarbital (2125)
|
II
|
Pentobarbital (2270)
|
II
|
Secobarbital (2315)
|
II
|
Phencyclidine (7471)
|
II
|
Cocaine (9041)
|
II
|
Codeine (9050)
|
II
|
Dihydrocodeine (9120)
|
II
|
Oxycodone (9143)
|
II
|
Hydromorphone (9150)
|
II
|
Benzoylecgonine (9180)
|
II
|
Ethylmorphine (9190)
|
II
|
Hydrocodone (9193)
|
II
|
Levorphanol (9220)
|
II
|
Meperidine (9230)
|
II
|
Methadone (9250)
|
II
|
Dextropropoxyphene, bulk (non-dosage forms) (9273)
|
II
|
Morphine (9300)
|
II
|
Thebaine (9333)
|
II
|
Oxymorphone (9652)
|
II
|
Alfentanil (9737)
|
II
|
Fentanyl (9801)
|
II
|
Sufentanil (9740)
|
II
|
The company plans to import analytical reference standards for distribution
to its customers for research and analytical purposes.
Any bulk manufacturer who is presently, or is applying to be, registered
with DEA to manufacture such basic classes of controlled substances listed in
schedule I or II, which fall under the authority of section 1002(a)(2)(B) of
the Act (21 U.S.C 952 (a)(2)(B) may file comments or objections to the
issuance of the proposed registration and may, at the same time, file a
written request for a hearing on such application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21 CFR
1316.47.
Any such comments or objections being sent via regular mail should be
addressed, in quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), Washington, DC
20537; or any being sent via express mail should be sent to Drug Enforcement
Administration, Office of Diversion Control, Federal Register Representative (ODL),
2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no
later than August 2, 2007.
This procedure is to be conducted simultaneously with and independent of
the procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the Federal Register on September 23, 1975,
(40 FR 43745), all applicants for registration to import a basic class of any
controlled substances in schedule I or II are and will continue to be required
to demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for such
registration pursuant to 21 U.S.C
958(a); 21 U.S.C
823(a); and 21 CFR
1301.34(b), (c), (d), (e) and (f) are satisfied.
[[Page 36483]]
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator,
Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. E7-12954 Filed 7-2-07; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|